secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092779
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q2 net loss $38.7M vs $1.4M income YoY; cash $503M, INVOKE-2 data on track for Q4 2024
--------------------------------------------------------------------------------

- Net loss of $38.7M ($0.40 per share) compared to net income of $1.4M in Q2 2023.
- Revenue fell to $15.1M from $56.2M YoY, primarily due to contract modifications on AL101 and AL002 programs.
- Cash, cash equivalents and investments total $503.3M, expected to fund operations through 2026.
- INVOKE-2 Phase 2 data for AL002 in early Alzheimer's disease anticipated in Q4 2024.
- FDA feedback supports potential path to approval for latozinemab in FTD-GRN using biomarkers as confirmatory evidence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024092779/0000950170-24-092779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024092779/alec-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer